Popular:
Arrowhead Pharmaceuticals, Inc. (ARWR)
Intrinsic Value
DCF Not Suitable for ARWR
Revenue ($597M) below $1B threshold — insufficient business scale for DCF.
Alternative Approach:
Use EV/Sales vs. industry peers for growth-stage companies.
Arrowhead Pharmaceuticals, Inc. (ARWR) Intrinsic Value
DCF-based fair value calculation with Bear, Base, and Bull scenarios
Frequently Asked Questions
Is ARWR stock undervalued or overvalued?
Insufficient data to compute DCF valuation for ARWR. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.
What is ARWR's intrinsic value?
Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.
How is ARWR's fair value calculated?
Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For ARWR, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.